nodes	percent_of_prediction	percent_of_DWPC	metapath
Lovastatin—ITGAL—psoriasis	0.484	1	CbGaD
Lovastatin—UGT2B7—Mycophenolic acid—psoriasis	0.037	0.0933	CbGbCtD
Lovastatin—UGT1A1—Mycophenolic acid—psoriasis	0.032	0.0806	CbGbCtD
Lovastatin—UGT2B7—Mycophenolate mofetil—psoriasis	0.0207	0.0521	CbGbCtD
Lovastatin—UGT1A1—Mycophenolate mofetil—psoriasis	0.0179	0.045	CbGbCtD
Lovastatin—CYP2C8—Tazarotene—psoriasis	0.0142	0.0357	CbGbCtD
Lovastatin—CYP3A5—Beclomethasone—psoriasis	0.0137	0.0345	CbGbCtD
Lovastatin—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0124	0.0312	CbGbCtD
Lovastatin—SLCO1A2—Prednisolone—psoriasis	0.0111	0.028	CbGbCtD
Lovastatin—ABCC2—Mycophenolate mofetil—psoriasis	0.0109	0.0274	CbGbCtD
Lovastatin—SLCO1A2—Hydrocortisone—psoriasis	0.0105	0.0265	CbGbCtD
Lovastatin—SLCO1A2—Prednisone—psoriasis	0.0105	0.0264	CbGbCtD
Lovastatin—SLCO1A2—Cyclosporine—psoriasis	0.00994	0.0251	CbGbCtD
Lovastatin—SLCO1B1—Cyclosporine—psoriasis	0.00938	0.0236	CbGbCtD
Lovastatin—ABCC2—Cyclosporine—psoriasis	0.00824	0.0208	CbGbCtD
Lovastatin—SLCO1A2—Dexamethasone—psoriasis	0.00655	0.0165	CbGbCtD
Lovastatin—CYP2D6—Hydroxyurea—psoriasis	0.00636	0.016	CbGbCtD
Lovastatin—CYP2C8—Cholecalciferol—psoriasis	0.00604	0.0152	CbGbCtD
Lovastatin—CYP3A7—Hydrocortisone—psoriasis	0.00583	0.0147	CbGbCtD
Lovastatin—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.00583	0.0147	CbGbCtD
Lovastatin—CYP3A7—Cyclosporine—psoriasis	0.0055	0.0139	CbGbCtD
Lovastatin—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0055	0.0139	CbGbCtD
Lovastatin—CYP3A5—Mycophenolate mofetil—psoriasis	0.00545	0.0137	CbGbCtD
Lovastatin—ABCC2—Dexamethasone—psoriasis	0.00543	0.0137	CbGbCtD
Lovastatin—SLCO1A2—Methotrexate—psoriasis	0.00526	0.0133	CbGbCtD
Lovastatin—CYP2C8—Mycophenolate mofetil—psoriasis	0.00524	0.0132	CbGbCtD
Lovastatin—CYP2C19—Cholecalciferol—psoriasis	0.00507	0.0128	CbGbCtD
Lovastatin—SLCO1B1—Methotrexate—psoriasis	0.00496	0.0125	CbGbCtD
Lovastatin—CYP3A4—Calcitriol—psoriasis	0.00476	0.012	CbGbCtD
Lovastatin—CYP3A5—Hydrocortisone—psoriasis	0.00437	0.011	CbGbCtD
Lovastatin—ABCC2—Methotrexate—psoriasis	0.00436	0.011	CbGbCtD
Lovastatin—CYP2C9—Cholecalciferol—psoriasis	0.00421	0.0106	CbGbCtD
Lovastatin—CYP2C8—Hydrocortisone—psoriasis	0.0042	0.0106	CbGbCtD
Lovastatin—CYP3A5—Cyclosporine—psoriasis	0.00413	0.0104	CbGbCtD
Lovastatin—CYP2C8—Cyclosporine—psoriasis	0.00397	0.01	CbGbCtD
Lovastatin—CYP2D6—Cholecalciferol—psoriasis	0.00385	0.00971	CbGbCtD
Lovastatin—CYP3A4—Methoxsalen—psoriasis	0.0037	0.00932	CbGbCtD
Lovastatin—CYP3A7—Dexamethasone—psoriasis	0.00362	0.00913	CbGbCtD
Lovastatin—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00362	0.00913	CbGbCtD
Lovastatin—ABCB1—Mycophenolate mofetil—psoriasis	0.00355	0.00893	CbGbCtD
Lovastatin—CYP2C19—Prednisone—psoriasis	0.00351	0.00885	CbGbCtD
Lovastatin—CYP2C19—Cyclosporine—psoriasis	0.00333	0.00839	CbGbCtD
Lovastatin—ABCB1—Betamethasone—psoriasis	0.00304	0.00766	CbGbCtD
Lovastatin—ABCB1—Prednisolone—psoriasis	0.003	0.00756	CbGbCtD
Lovastatin—ABCB1—Hydrocortisone—psoriasis	0.00285	0.00717	CbGbCtD
Lovastatin—ABCB1—Prednisone—psoriasis	0.00283	0.00714	CbGbCtD
Lovastatin—CYP2C9—Cyclosporine—psoriasis	0.00277	0.00698	CbGbCtD
Lovastatin—CYP3A5—Dexamethasone—psoriasis	0.00272	0.00685	CbGbCtD
Lovastatin—ABCB1—Cyclosporine—psoriasis	0.00269	0.00677	CbGbCtD
Lovastatin—CYP2C8—Dexamethasone—psoriasis	0.00261	0.00659	CbGbCtD
Lovastatin—CYP2D6—Cyclosporine—psoriasis	0.00253	0.00638	CbGbCtD
Lovastatin—CYP3A4—Cholecalciferol—psoriasis	0.00245	0.00617	CbGbCtD
Lovastatin—CYP2C19—Dexamethasone—psoriasis	0.00219	0.00553	CbGbCtD
Lovastatin—CYP3A4—Mycophenolate mofetil—psoriasis	0.00212	0.00535	CbGbCtD
Lovastatin—CYP3A4—Triamcinolone—psoriasis	0.00212	0.00535	CbGbCtD
Lovastatin—CYP2C9—Dexamethasone—psoriasis	0.00182	0.00459	CbGbCtD
Lovastatin—CYP3A4—Betamethasone—psoriasis	0.00182	0.00459	CbGbCtD
Lovastatin—CYP3A4—Prednisolone—psoriasis	0.0018	0.00453	CbGbCtD
Lovastatin—ABCB1—Dexamethasone—psoriasis	0.00177	0.00446	CbGbCtD
Lovastatin—CYP3A4—Hydrocortisone—psoriasis	0.00171	0.0043	CbGbCtD
Lovastatin—CYP3A4—Prednisone—psoriasis	0.0017	0.00428	CbGbCtD
Lovastatin—CYP2D6—Dexamethasone—psoriasis	0.00167	0.0042	CbGbCtD
Lovastatin—CYP3A4—Cyclosporine—psoriasis	0.00161	0.00406	CbGbCtD
Lovastatin—HDAC2—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.00145	0.953	CbGdCrCtD
Lovastatin—ABCB1—Methotrexate—psoriasis	0.00142	0.00358	CbGbCtD
Lovastatin—CYP3A4—Dexamethasone—psoriasis	0.00106	0.00267	CbGbCtD
Lovastatin—HDAC2—Levonorgestrel—Hydrocortisone—psoriasis	7.19e-05	0.0472	CbGdCrCtD
Lovastatin—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	6.84e-05	0.00202	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—PCNA—psoriasis	6.6e-05	0.00195	CbGpPWpGaD
Lovastatin—CYP2D6—Biological oxidations—CYP2S1—psoriasis	6.59e-05	0.00195	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of Telomerase—JUN—psoriasis	6.56e-05	0.00194	CbGpPWpGaD
Lovastatin—CYP2C9—Biological oxidations—CYP2S1—psoriasis	6.53e-05	0.00193	CbGpPWpGaD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—IFNG—psoriasis	6.53e-05	0.00193	CbGpPWpGaD
Lovastatin—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	6.5e-05	0.00192	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—NOS2—psoriasis	6.46e-05	0.00191	CbGpPWpGaD
Lovastatin—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	6.44e-05	0.0019	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—HLA-A—psoriasis	6.42e-05	0.0019	CbGpPWpGaD
Lovastatin—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	6.39e-05	0.00189	CbGpPWpGaD
Lovastatin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	6.31e-05	0.00186	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of Telomerase—NFKB1—psoriasis	6.31e-05	0.00186	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	6.19e-05	0.00183	CbGpPWpGaD
Lovastatin—HDAC2—Notch Signaling Pathway—STAT3—psoriasis	6.19e-05	0.00183	CbGpPWpGaD
Lovastatin—HDAC2—Signaling events mediated by HDAC Class I—NFKB1—psoriasis	6.17e-05	0.00182	CbGpPWpGaD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—CXCL8—psoriasis	6.07e-05	0.00179	CbGpPWpGaD
Lovastatin—Paraesthesia—Mycophenolate mofetil—psoriasis	6.04e-05	0.000725	CcSEcCtD
Lovastatin—Pruritus—Mycophenolic acid—psoriasis	6.03e-05	0.000724	CcSEcCtD
Lovastatin—Myalgia—Triamcinolone—psoriasis	6.02e-05	0.000722	CcSEcCtD
Lovastatin—SLCO1A2—SLC-mediated transmembrane transport—CP—psoriasis	6.01e-05	0.00177	CbGpPWpGaD
Lovastatin—Dyspnoea—Mycophenolate mofetil—psoriasis	5.99e-05	0.00072	CcSEcCtD
Lovastatin—Decreased appetite—Cyclosporine—psoriasis	5.99e-05	0.000719	CcSEcCtD
Lovastatin—Flushing—Prednisone—psoriasis	5.95e-05	0.000715	CcSEcCtD
Lovastatin—Ill-defined disorder—Dexamethasone—psoriasis	5.95e-05	0.000714	CcSEcCtD
Lovastatin—Ill-defined disorder—Betamethasone—psoriasis	5.95e-05	0.000714	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—HLA-C—psoriasis	5.95e-05	0.00176	CbGpPWpGaD
Lovastatin—Discomfort—Triamcinolone—psoriasis	5.94e-05	0.000714	CcSEcCtD
Lovastatin—Fatigue—Cyclosporine—psoriasis	5.94e-05	0.000713	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Methotrexate—psoriasis	5.92e-05	0.000711	CcSEcCtD
Lovastatin—Dyspepsia—Mycophenolate mofetil—psoriasis	5.92e-05	0.00071	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—IL13—psoriasis	5.91e-05	0.00175	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—HLA-E—psoriasis	5.9e-05	0.00174	CbGpPWpGaD
Lovastatin—Pain—Cyclosporine—psoriasis	5.89e-05	0.000708	CcSEcCtD
Lovastatin—Constipation—Cyclosporine—psoriasis	5.89e-05	0.000708	CcSEcCtD
Lovastatin—Dry mouth—Triamcinolone—psoriasis	5.88e-05	0.000706	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—HLA-DRB1—psoriasis	5.86e-05	0.00173	CbGpPWpGaD
Lovastatin—Angioedema—Dexamethasone—psoriasis	5.86e-05	0.000703	CcSEcCtD
Lovastatin—Angioedema—Betamethasone—psoriasis	5.86e-05	0.000703	CcSEcCtD
Lovastatin—Decreased appetite—Mycophenolate mofetil—psoriasis	5.84e-05	0.000702	CcSEcCtD
Lovastatin—Anorexia—Hydrocortisone—psoriasis	5.84e-05	0.000701	CcSEcCtD
Lovastatin—Diarrhoea—Mycophenolic acid—psoriasis	5.83e-05	0.0007	CcSEcCtD
Lovastatin—Malaise—Dexamethasone—psoriasis	5.78e-05	0.000694	CcSEcCtD
Lovastatin—Malaise—Betamethasone—psoriasis	5.78e-05	0.000694	CcSEcCtD
Lovastatin—Anaphylactic shock—Triamcinolone—psoriasis	5.77e-05	0.000692	CcSEcCtD
Lovastatin—Vertigo—Betamethasone—psoriasis	5.76e-05	0.000692	CcSEcCtD
Lovastatin—Vertigo—Dexamethasone—psoriasis	5.76e-05	0.000692	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	5.76e-05	0.0017	CbGpPWpGaD
Lovastatin—Pain—Mycophenolate mofetil—psoriasis	5.75e-05	0.00069	CcSEcCtD
Lovastatin—Constipation—Mycophenolate mofetil—psoriasis	5.75e-05	0.00069	CcSEcCtD
Lovastatin—Infection—Triamcinolone—psoriasis	5.73e-05	0.000688	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	5.7e-05	0.00168	CbGpPWpGaD
Lovastatin—Feeling abnormal—Cyclosporine—psoriasis	5.68e-05	0.000682	CcSEcCtD
Lovastatin—Insomnia—Prednisolone—psoriasis	5.67e-05	0.000681	CcSEcCtD
Lovastatin—Alopecia—Prednisone—psoriasis	5.67e-05	0.00068	CcSEcCtD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—JUN—psoriasis	5.64e-05	0.00167	CbGpPWpGaD
Lovastatin—Gastrointestinal pain—Cyclosporine—psoriasis	5.64e-05	0.000677	CcSEcCtD
Lovastatin—Dizziness—Mycophenolic acid—psoriasis	5.63e-05	0.000676	CcSEcCtD
Lovastatin—Paraesthesia—Prednisolone—psoriasis	5.63e-05	0.000676	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—ICAM1—psoriasis	5.63e-05	0.00166	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—NFKBIA—psoriasis	5.58e-05	0.00165	CbGpPWpGaD
Lovastatin—Musculoskeletal discomfort—Hydrocortisone—psoriasis	5.58e-05	0.00067	CcSEcCtD
Lovastatin—HDAC2—Signaling events mediated by HDAC Class I—STAT3—psoriasis	5.54e-05	0.00164	CbGpPWpGaD
Lovastatin—Feeling abnormal—Mycophenolate mofetil—psoriasis	5.54e-05	0.000665	CcSEcCtD
Lovastatin—Insomnia—Hydrocortisone—psoriasis	5.54e-05	0.000665	CcSEcCtD
Lovastatin—Paraesthesia—Hydrocortisone—psoriasis	5.5e-05	0.00066	CcSEcCtD
Lovastatin—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	5.5e-05	0.00066	CcSEcCtD
Lovastatin—Urticaria—Cyclosporine—psoriasis	5.47e-05	0.000657	CcSEcCtD
Lovastatin—Myalgia—Dexamethasone—psoriasis	5.46e-05	0.000655	CcSEcCtD
Lovastatin—Myalgia—Betamethasone—psoriasis	5.46e-05	0.000655	CcSEcCtD
Lovastatin—Body temperature increased—Cyclosporine—psoriasis	5.45e-05	0.000654	CcSEcCtD
Lovastatin—Abdominal pain—Cyclosporine—psoriasis	5.45e-05	0.000654	CcSEcCtD
Lovastatin—HMGCR—Metabolism—NDUFA5—psoriasis	5.44e-05	0.00161	CbGpPWpGaD
Lovastatin—Anxiety—Dexamethasone—psoriasis	5.44e-05	0.000653	CcSEcCtD
Lovastatin—Anxiety—Betamethasone—psoriasis	5.44e-05	0.000653	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—IL17A—psoriasis	5.44e-05	0.00161	CbGpPWpGaD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—NFKB1—psoriasis	5.43e-05	0.0016	CbGpPWpGaD
Lovastatin—HDAC2—p75 NTR receptor-mediated signalling—NFKB1—psoriasis	5.43e-05	0.0016	CbGpPWpGaD
Lovastatin—Vomiting—Mycophenolic acid—psoriasis	5.42e-05	0.00065	CcSEcCtD
Lovastatin—Discomfort—Betamethasone—psoriasis	5.39e-05	0.000647	CcSEcCtD
Lovastatin—Discomfort—Dexamethasone—psoriasis	5.39e-05	0.000647	CcSEcCtD
Lovastatin—Dyspepsia—Hydrocortisone—psoriasis	5.39e-05	0.000647	CcSEcCtD
Lovastatin—Rash—Mycophenolic acid—psoriasis	5.37e-05	0.000645	CcSEcCtD
Lovastatin—Dermatitis—Mycophenolic acid—psoriasis	5.37e-05	0.000644	CcSEcCtD
Lovastatin—Pain—Prednisolone—psoriasis	5.36e-05	0.000644	CcSEcCtD
Lovastatin—Hepatitis—Methotrexate—psoriasis	5.36e-05	0.000644	CcSEcCtD
Lovastatin—HMGCR—AMPK Signaling—TP53—psoriasis	5.35e-05	0.00158	CbGpPWpGaD
Lovastatin—Urticaria—Mycophenolate mofetil—psoriasis	5.34e-05	0.000641	CcSEcCtD
Lovastatin—Headache—Mycophenolic acid—psoriasis	5.34e-05	0.000641	CcSEcCtD
Lovastatin—Decreased appetite—Hydrocortisone—psoriasis	5.32e-05	0.000639	CcSEcCtD
Lovastatin—Abdominal pain—Mycophenolate mofetil—psoriasis	5.31e-05	0.000638	CcSEcCtD
Lovastatin—Body temperature increased—Mycophenolate mofetil—psoriasis	5.31e-05	0.000638	CcSEcCtD
Lovastatin—HMGCR—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	5.31e-05	0.00157	CbGpPWpGaD
Lovastatin—Fatigue—Hydrocortisone—psoriasis	5.28e-05	0.000634	CcSEcCtD
Lovastatin—Vision blurred—Prednisone—psoriasis	5.26e-05	0.000632	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Triamcinolone—psoriasis	5.25e-05	0.000631	CcSEcCtD
Lovastatin—Pain—Hydrocortisone—psoriasis	5.24e-05	0.000629	CcSEcCtD
Lovastatin—Anaphylactic shock—Dexamethasone—psoriasis	5.23e-05	0.000628	CcSEcCtD
Lovastatin—Anaphylactic shock—Betamethasone—psoriasis	5.23e-05	0.000628	CcSEcCtD
Lovastatin—Insomnia—Triamcinolone—psoriasis	5.22e-05	0.000626	CcSEcCtD
Lovastatin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.2e-05	0.00154	CbGpPWpGaD
Lovastatin—Infection—Betamethasone—psoriasis	5.2e-05	0.000624	CcSEcCtD
Lovastatin—Infection—Dexamethasone—psoriasis	5.2e-05	0.000624	CcSEcCtD
Lovastatin—Ill-defined disorder—Prednisone—psoriasis	5.18e-05	0.000622	CcSEcCtD
Lovastatin—Paraesthesia—Triamcinolone—psoriasis	5.18e-05	0.000622	CcSEcCtD
Lovastatin—Feeling abnormal—Prednisolone—psoriasis	5.17e-05	0.00062	CcSEcCtD
Lovastatin—Dyspnoea—Triamcinolone—psoriasis	5.14e-05	0.000617	CcSEcCtD
Lovastatin—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	5.14e-05	0.00152	CbGpPWpGaD
Lovastatin—Thrombocytopenia—Dexamethasone—psoriasis	5.12e-05	0.000615	CcSEcCtD
Lovastatin—Thrombocytopenia—Betamethasone—psoriasis	5.12e-05	0.000615	CcSEcCtD
Lovastatin—Angioedema—Prednisone—psoriasis	5.1e-05	0.000613	CcSEcCtD
Lovastatin—Hypersensitivity—Cyclosporine—psoriasis	5.08e-05	0.00061	CcSEcCtD
Lovastatin—Dyspepsia—Triamcinolone—psoriasis	5.08e-05	0.000609	CcSEcCtD
Lovastatin—HMGCR—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.08e-05	0.0015	CbGpPWpGaD
Lovastatin—Erythema multiforme—Methotrexate—psoriasis	5.07e-05	0.000608	CcSEcCtD
Lovastatin—Nausea—Mycophenolic acid—psoriasis	5.06e-05	0.000607	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—IL12B—psoriasis	5.06e-05	0.00149	CbGpPWpGaD
Lovastatin—Feeling abnormal—Hydrocortisone—psoriasis	5.05e-05	0.000606	CcSEcCtD
Lovastatin—Malaise—Prednisone—psoriasis	5.03e-05	0.000605	CcSEcCtD
Lovastatin—Vertigo—Prednisone—psoriasis	5.02e-05	0.000602	CcSEcCtD
Lovastatin—Gastrointestinal pain—Hydrocortisone—psoriasis	5.01e-05	0.000601	CcSEcCtD
Lovastatin—Anorexia—Dexamethasone—psoriasis	4.99e-05	0.000599	CcSEcCtD
Lovastatin—Anorexia—Betamethasone—psoriasis	4.99e-05	0.000599	CcSEcCtD
Lovastatin—Urticaria—Prednisolone—psoriasis	4.98e-05	0.000598	CcSEcCtD
Lovastatin—Fatigue—Triamcinolone—psoriasis	4.97e-05	0.000597	CcSEcCtD
Lovastatin—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.95e-05	0.000595	CcSEcCtD
Lovastatin—Asthenia—Cyclosporine—psoriasis	4.94e-05	0.000594	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—HLA-E—psoriasis	4.94e-05	0.00146	CbGpPWpGaD
Lovastatin—Pain—Triamcinolone—psoriasis	4.93e-05	0.000592	CcSEcCtD
Lovastatin—ITGAL—Immune System—SOCS1—psoriasis	4.92e-05	0.00145	CbGpPWpGaD
Lovastatin—Pruritus—Cyclosporine—psoriasis	4.88e-05	0.000585	CcSEcCtD
Lovastatin—Urticaria—Hydrocortisone—psoriasis	4.87e-05	0.000584	CcSEcCtD
Lovastatin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.86e-05	0.00144	CbGpPWpGaD
Lovastatin—Abdominal pain—Hydrocortisone—psoriasis	4.84e-05	0.000581	CcSEcCtD
Lovastatin—Body temperature increased—Hydrocortisone—psoriasis	4.84e-05	0.000581	CcSEcCtD
Lovastatin—HDAC2—Hemostasis—ITGAL—psoriasis	4.84e-05	0.00143	CbGpPWpGaD
Lovastatin—Asthenia—Mycophenolate mofetil—psoriasis	4.82e-05	0.000579	CcSEcCtD
Lovastatin—Chills—Methotrexate—psoriasis	4.81e-05	0.000577	CcSEcCtD
Lovastatin—HDAC2—Signaling events mediated by HDAC Class I—TNF—psoriasis	4.8e-05	0.00142	CbGpPWpGaD
Lovastatin—Musculoskeletal discomfort—Betamethasone—psoriasis	4.77e-05	0.000572	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.77e-05	0.000572	CcSEcCtD
Lovastatin—Pruritus—Mycophenolate mofetil—psoriasis	4.76e-05	0.000571	CcSEcCtD
Lovastatin—Myalgia—Prednisone—psoriasis	4.75e-05	0.000571	CcSEcCtD
Lovastatin—Arthralgia—Prednisone—psoriasis	4.75e-05	0.000571	CcSEcCtD
Lovastatin—Feeling abnormal—Triamcinolone—psoriasis	4.75e-05	0.000571	CcSEcCtD
Lovastatin—Anxiety—Prednisone—psoriasis	4.74e-05	0.000569	CcSEcCtD
Lovastatin—Alopecia—Methotrexate—psoriasis	4.74e-05	0.000569	CcSEcCtD
Lovastatin—Insomnia—Dexamethasone—psoriasis	4.73e-05	0.000568	CcSEcCtD
Lovastatin—Insomnia—Betamethasone—psoriasis	4.73e-05	0.000568	CcSEcCtD
Lovastatin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.73e-05	0.0014	CbGpPWpGaD
Lovastatin—Diarrhoea—Cyclosporine—psoriasis	4.71e-05	0.000566	CcSEcCtD
Lovastatin—Paraesthesia—Betamethasone—psoriasis	4.7e-05	0.000564	CcSEcCtD
Lovastatin—Paraesthesia—Dexamethasone—psoriasis	4.7e-05	0.000564	CcSEcCtD
Lovastatin—Discomfort—Prednisone—psoriasis	4.7e-05	0.000564	CcSEcCtD
Lovastatin—HMGCR—Metabolism—CYP2S1—psoriasis	4.63e-05	0.00137	CbGpPWpGaD
Lovastatin—Hypersensitivity—Prednisolone—psoriasis	4.62e-05	0.000555	CcSEcCtD
Lovastatin—Dyspepsia—Dexamethasone—psoriasis	4.61e-05	0.000553	CcSEcCtD
Lovastatin—Dyspepsia—Betamethasone—psoriasis	4.61e-05	0.000553	CcSEcCtD
Lovastatin—Diarrhoea—Mycophenolate mofetil—psoriasis	4.6e-05	0.000552	CcSEcCtD
Lovastatin—HDAC2—Neural Crest Differentiation—NFKB1—psoriasis	4.6e-05	0.00136	CbGpPWpGaD
Lovastatin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.6e-05	0.00136	CbGpPWpGaD
Lovastatin—Urticaria—Triamcinolone—psoriasis	4.58e-05	0.00055	CcSEcCtD
Lovastatin—Dysgeusia—Methotrexate—psoriasis	4.57e-05	0.000549	CcSEcCtD
Lovastatin—Body temperature increased—Triamcinolone—psoriasis	4.56e-05	0.000547	CcSEcCtD
Lovastatin—Dizziness—Cyclosporine—psoriasis	4.56e-05	0.000547	CcSEcCtD
Lovastatin—Anaphylactic shock—Prednisone—psoriasis	4.56e-05	0.000547	CcSEcCtD
Lovastatin—Decreased appetite—Dexamethasone—psoriasis	4.55e-05	0.000546	CcSEcCtD
Lovastatin—Decreased appetite—Betamethasone—psoriasis	4.55e-05	0.000546	CcSEcCtD
Lovastatin—Infection—Prednisone—psoriasis	4.53e-05	0.000544	CcSEcCtD
Lovastatin—Back pain—Methotrexate—psoriasis	4.51e-05	0.000542	CcSEcCtD
Lovastatin—Hypersensitivity—Hydrocortisone—psoriasis	4.51e-05	0.000542	CcSEcCtD
Lovastatin—Fatigue—Dexamethasone—psoriasis	4.51e-05	0.000542	CcSEcCtD
Lovastatin—Fatigue—Betamethasone—psoriasis	4.51e-05	0.000542	CcSEcCtD
Lovastatin—HDAC2—Signaling by NOTCH—JUN—psoriasis	4.49e-05	0.00133	CbGpPWpGaD
Lovastatin—Pain—Betamethasone—psoriasis	4.47e-05	0.000537	CcSEcCtD
Lovastatin—Pain—Dexamethasone—psoriasis	4.47e-05	0.000537	CcSEcCtD
Lovastatin—HDAC2—Circadian rythm related genes—LEP—psoriasis	4.46e-05	0.00132	CbGpPWpGaD
Lovastatin—Dizziness—Mycophenolate mofetil—psoriasis	4.45e-05	0.000534	CcSEcCtD
Lovastatin—UGT1A3—Metabolism—NDUFA5—psoriasis	4.44e-05	0.00131	CbGpPWpGaD
Lovastatin—Vision blurred—Methotrexate—psoriasis	4.4e-05	0.000528	CcSEcCtD
Lovastatin—Asthenia—Hydrocortisone—psoriasis	4.39e-05	0.000528	CcSEcCtD
Lovastatin—Vomiting—Cyclosporine—psoriasis	4.38e-05	0.000526	CcSEcCtD
Lovastatin—ITGAL—Immune System—CD8A—psoriasis	4.37e-05	0.00129	CbGpPWpGaD
Lovastatin—Rash—Cyclosporine—psoriasis	4.34e-05	0.000522	CcSEcCtD
Lovastatin—Anorexia—Prednisone—psoriasis	4.34e-05	0.000521	CcSEcCtD
Lovastatin—Dermatitis—Cyclosporine—psoriasis	4.34e-05	0.000521	CcSEcCtD
Lovastatin—Pruritus—Hydrocortisone—psoriasis	4.33e-05	0.00052	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—JUN—psoriasis	4.33e-05	0.00128	CbGpPWpGaD
Lovastatin—Ill-defined disorder—Methotrexate—psoriasis	4.33e-05	0.00052	CcSEcCtD
Lovastatin—Headache—Cyclosporine—psoriasis	4.32e-05	0.000518	CcSEcCtD
Lovastatin—Feeling abnormal—Betamethasone—psoriasis	4.31e-05	0.000518	CcSEcCtD
Lovastatin—Feeling abnormal—Dexamethasone—psoriasis	4.31e-05	0.000518	CcSEcCtD
Lovastatin—CYP3A4—Biological oxidations—CYP2S1—psoriasis	4.31e-05	0.00127	CbGpPWpGaD
Lovastatin—Gastrointestinal pain—Betamethasone—psoriasis	4.28e-05	0.000514	CcSEcCtD
Lovastatin—Gastrointestinal pain—Dexamethasone—psoriasis	4.28e-05	0.000514	CcSEcCtD
Lovastatin—Vomiting—Mycophenolate mofetil—psoriasis	4.27e-05	0.000513	CcSEcCtD
Lovastatin—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	4.25e-05	0.00126	CbGpPWpGaD
Lovastatin—Hypersensitivity—Triamcinolone—psoriasis	4.25e-05	0.00051	CcSEcCtD
Lovastatin—Rash—Mycophenolate mofetil—psoriasis	4.24e-05	0.000509	CcSEcCtD
Lovastatin—Dermatitis—Mycophenolate mofetil—psoriasis	4.23e-05	0.000508	CcSEcCtD
Lovastatin—Headache—Mycophenolate mofetil—psoriasis	4.21e-05	0.000506	CcSEcCtD
Lovastatin—Malaise—Methotrexate—psoriasis	4.21e-05	0.000505	CcSEcCtD
Lovastatin—ITGAL—Immune System—HLA-B—psoriasis	4.2e-05	0.00124	CbGpPWpGaD
Lovastatin—Vertigo—Methotrexate—psoriasis	4.19e-05	0.000503	CcSEcCtD
Lovastatin—Diarrhoea—Hydrocortisone—psoriasis	4.19e-05	0.000503	CcSEcCtD
Lovastatin—Leukopenia—Methotrexate—psoriasis	4.18e-05	0.000501	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	4.17e-05	0.00123	CbGpPWpGaD
Lovastatin—Urticaria—Dexamethasone—psoriasis	4.16e-05	0.000499	CcSEcCtD
Lovastatin—Urticaria—Betamethasone—psoriasis	4.16e-05	0.000499	CcSEcCtD
Lovastatin—HDAC2—Circadian rythm related genes—NOS2—psoriasis	4.15e-05	0.00123	CbGpPWpGaD
Lovastatin—Musculoskeletal discomfort—Prednisone—psoriasis	4.15e-05	0.000498	CcSEcCtD
Lovastatin—Dizziness—Prednisolone—psoriasis	4.15e-05	0.000498	CcSEcCtD
Lovastatin—Asthenia—Triamcinolone—psoriasis	4.14e-05	0.000497	CcSEcCtD
Lovastatin—Body temperature increased—Dexamethasone—psoriasis	4.14e-05	0.000497	CcSEcCtD
Lovastatin—Abdominal pain—Betamethasone—psoriasis	4.14e-05	0.000497	CcSEcCtD
Lovastatin—Abdominal pain—Dexamethasone—psoriasis	4.14e-05	0.000497	CcSEcCtD
Lovastatin—Body temperature increased—Betamethasone—psoriasis	4.14e-05	0.000497	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—CD4—psoriasis	4.14e-05	0.00122	CbGpPWpGaD
Lovastatin—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	4.13e-05	0.00122	CbGpPWpGaD
Lovastatin—Insomnia—Prednisone—psoriasis	4.12e-05	0.000495	CcSEcCtD
Lovastatin—Nausea—Cyclosporine—psoriasis	4.09e-05	0.000491	CcSEcCtD
Lovastatin—Paraesthesia—Prednisone—psoriasis	4.09e-05	0.000491	CcSEcCtD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	4.08e-05	0.00121	CbGpPWpGaD
Lovastatin—Pruritus—Triamcinolone—psoriasis	4.08e-05	0.00049	CcSEcCtD
Lovastatin—Dizziness—Hydrocortisone—psoriasis	4.05e-05	0.000486	CcSEcCtD
Lovastatin—Dyspepsia—Prednisone—psoriasis	4.01e-05	0.000482	CcSEcCtD
Lovastatin—Nausea—Mycophenolate mofetil—psoriasis	3.99e-05	0.000479	CcSEcCtD
Lovastatin—Arthralgia—Methotrexate—psoriasis	3.97e-05	0.000477	CcSEcCtD
Lovastatin—Chest pain—Methotrexate—psoriasis	3.97e-05	0.000477	CcSEcCtD
Lovastatin—Myalgia—Methotrexate—psoriasis	3.97e-05	0.000477	CcSEcCtD
Lovastatin—Decreased appetite—Prednisone—psoriasis	3.96e-05	0.000476	CcSEcCtD
Lovastatin—Rash—Prednisolone—psoriasis	3.95e-05	0.000475	CcSEcCtD
Lovastatin—Dermatitis—Prednisolone—psoriasis	3.95e-05	0.000474	CcSEcCtD
Lovastatin—Fatigue—Prednisone—psoriasis	3.93e-05	0.000472	CcSEcCtD
Lovastatin—Headache—Prednisolone—psoriasis	3.93e-05	0.000472	CcSEcCtD
Lovastatin—Discomfort—Methotrexate—psoriasis	3.92e-05	0.000471	CcSEcCtD
Lovastatin—Constipation—Prednisone—psoriasis	3.9e-05	0.000468	CcSEcCtD
Lovastatin—Vomiting—Hydrocortisone—psoriasis	3.89e-05	0.000468	CcSEcCtD
Lovastatin—ITGAL—Immune System—HLA-A—psoriasis	3.89e-05	0.00115	CbGpPWpGaD
Lovastatin—HDAC2—Circadian rythm related genes—PPARG—psoriasis	3.88e-05	0.00115	CbGpPWpGaD
Lovastatin—Rash—Hydrocortisone—psoriasis	3.86e-05	0.000464	CcSEcCtD
Lovastatin—Dermatitis—Hydrocortisone—psoriasis	3.86e-05	0.000463	CcSEcCtD
Lovastatin—Confusional state—Methotrexate—psoriasis	3.84e-05	0.000461	CcSEcCtD
Lovastatin—Headache—Hydrocortisone—psoriasis	3.84e-05	0.000461	CcSEcCtD
Lovastatin—Dizziness—Triamcinolone—psoriasis	3.81e-05	0.000458	CcSEcCtD
Lovastatin—Anaphylactic shock—Methotrexate—psoriasis	3.81e-05	0.000457	CcSEcCtD
Lovastatin—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	3.8e-05	0.00112	CbGpPWpGaD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	3.78e-05	0.00112	CbGpPWpGaD
Lovastatin—Infection—Methotrexate—psoriasis	3.78e-05	0.000454	CcSEcCtD
Lovastatin—UGT1A3—Metabolism—CYP2S1—psoriasis	3.77e-05	0.00111	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—NDUFA5—psoriasis	3.77e-05	0.00111	CbGpPWpGaD
Lovastatin—Feeling abnormal—Prednisone—psoriasis	3.75e-05	0.000451	CcSEcCtD
Lovastatin—Asthenia—Dexamethasone—psoriasis	3.75e-05	0.000451	CcSEcCtD
Lovastatin—Asthenia—Betamethasone—psoriasis	3.75e-05	0.000451	CcSEcCtD
Lovastatin—ITGAL—Hemostasis—VEGFA—psoriasis	3.74e-05	0.0011	CbGpPWpGaD
Lovastatin—Thrombocytopenia—Methotrexate—psoriasis	3.73e-05	0.000448	CcSEcCtD
Lovastatin—Gastrointestinal pain—Prednisone—psoriasis	3.73e-05	0.000447	CcSEcCtD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—TP53—psoriasis	3.73e-05	0.0011	CbGpPWpGaD
Lovastatin—Nausea—Prednisolone—psoriasis	3.72e-05	0.000447	CcSEcCtD
Lovastatin—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.72e-05	0.0011	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—CRP—psoriasis	3.71e-05	0.0011	CbGpPWpGaD
Lovastatin—Pruritus—Dexamethasone—psoriasis	3.7e-05	0.000444	CcSEcCtD
Lovastatin—Pruritus—Betamethasone—psoriasis	3.7e-05	0.000444	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—IL10—psoriasis	3.7e-05	0.00109	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—JUN—psoriasis	3.68e-05	0.00109	CbGpPWpGaD
Lovastatin—Vomiting—Triamcinolone—psoriasis	3.67e-05	0.00044	CcSEcCtD
Lovastatin—Nausea—Hydrocortisone—psoriasis	3.64e-05	0.000437	CcSEcCtD
Lovastatin—Rash—Triamcinolone—psoriasis	3.64e-05	0.000437	CcSEcCtD
Lovastatin—Dermatitis—Triamcinolone—psoriasis	3.63e-05	0.000436	CcSEcCtD
Lovastatin—Anorexia—Methotrexate—psoriasis	3.63e-05	0.000436	CcSEcCtD
Lovastatin—Urticaria—Prednisone—psoriasis	3.62e-05	0.000435	CcSEcCtD
Lovastatin—Headache—Triamcinolone—psoriasis	3.61e-05	0.000434	CcSEcCtD
Lovastatin—Body temperature increased—Prednisone—psoriasis	3.6e-05	0.000432	CcSEcCtD
Lovastatin—Abdominal pain—Prednisone—psoriasis	3.6e-05	0.000432	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—IL4—psoriasis	3.6e-05	0.00106	CbGpPWpGaD
Lovastatin—Diarrhoea—Dexamethasone—psoriasis	3.58e-05	0.00043	CcSEcCtD
Lovastatin—Diarrhoea—Betamethasone—psoriasis	3.58e-05	0.00043	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—NFKB1—psoriasis	3.56e-05	0.00105	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—HLA-DRB1—psoriasis	3.56e-05	0.00105	CbGpPWpGaD
Lovastatin—ABCB1—Allograft Rejection—HLA-B—psoriasis	3.52e-05	0.00104	CbGpPWpGaD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	3.51e-05	0.00104	CbGpPWpGaD
Lovastatin—Musculoskeletal discomfort—Methotrexate—psoriasis	3.47e-05	0.000417	CcSEcCtD
Lovastatin—Dizziness—Dexamethasone—psoriasis	3.46e-05	0.000415	CcSEcCtD
Lovastatin—Dizziness—Betamethasone—psoriasis	3.46e-05	0.000415	CcSEcCtD
Lovastatin—Insomnia—Methotrexate—psoriasis	3.44e-05	0.000414	CcSEcCtD
Lovastatin—Nausea—Triamcinolone—psoriasis	3.43e-05	0.000411	CcSEcCtD
Lovastatin—HDAC2—Signaling Pathways—HCAR2—psoriasis	3.42e-05	0.00101	CbGpPWpGaD
Lovastatin—Paraesthesia—Methotrexate—psoriasis	3.42e-05	0.000411	CcSEcCtD
Lovastatin—ITGAL—Immune System—ICAM1—psoriasis	3.41e-05	0.00101	CbGpPWpGaD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—IL6—psoriasis	3.41e-05	0.00101	CbGpPWpGaD
Lovastatin—Dyspnoea—Methotrexate—psoriasis	3.4e-05	0.000408	CcSEcCtD
Lovastatin—ITGAL—Immune System—NFKBIA—psoriasis	3.39e-05	0.001	CbGpPWpGaD
Lovastatin—Hypersensitivity—Prednisone—psoriasis	3.36e-05	0.000403	CcSEcCtD
Lovastatin—Dyspepsia—Methotrexate—psoriasis	3.35e-05	0.000402	CcSEcCtD
Lovastatin—Vomiting—Betamethasone—psoriasis	3.33e-05	0.000399	CcSEcCtD
Lovastatin—Vomiting—Dexamethasone—psoriasis	3.33e-05	0.000399	CcSEcCtD
Lovastatin—Decreased appetite—Methotrexate—psoriasis	3.31e-05	0.000397	CcSEcCtD
Lovastatin—Rash—Dexamethasone—psoriasis	3.3e-05	0.000396	CcSEcCtD
Lovastatin—Rash—Betamethasone—psoriasis	3.3e-05	0.000396	CcSEcCtD
Lovastatin—Dermatitis—Dexamethasone—psoriasis	3.3e-05	0.000396	CcSEcCtD
Lovastatin—Dermatitis—Betamethasone—psoriasis	3.3e-05	0.000396	CcSEcCtD
Lovastatin—SLCO1A2—Metabolism—NDUFA5—psoriasis	3.29e-05	0.000971	CbGpPWpGaD
Lovastatin—Fatigue—Methotrexate—psoriasis	3.28e-05	0.000394	CcSEcCtD
Lovastatin—Headache—Betamethasone—psoriasis	3.28e-05	0.000394	CcSEcCtD
Lovastatin—Headache—Dexamethasone—psoriasis	3.28e-05	0.000394	CcSEcCtD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	3.27e-05	0.000967	CbGpPWpGaD
Lovastatin—Asthenia—Prednisone—psoriasis	3.27e-05	0.000393	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—HLA-A—psoriasis	3.26e-05	0.000962	CbGpPWpGaD
Lovastatin—Pain—Methotrexate—psoriasis	3.26e-05	0.000391	CcSEcCtD
Lovastatin—Pruritus—Prednisone—psoriasis	3.22e-05	0.000387	CcSEcCtD
Lovastatin—UGT2B7—Metabolism—CYP2S1—psoriasis	3.21e-05	0.000948	CbGpPWpGaD
Lovastatin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.2e-05	0.000946	CbGpPWpGaD
Lovastatin—Feeling abnormal—Methotrexate—psoriasis	3.14e-05	0.000377	CcSEcCtD
Lovastatin—HDAC2—Signaling by NGF—NFKBIA—psoriasis	3.13e-05	0.000925	CbGpPWpGaD
Lovastatin—HDAC2—Cell Cycle—TP53—psoriasis	3.13e-05	0.000924	CbGpPWpGaD
Lovastatin—Diarrhoea—Prednisone—psoriasis	3.12e-05	0.000374	CcSEcCtD
Lovastatin—Gastrointestinal pain—Methotrexate—psoriasis	3.11e-05	0.000374	CcSEcCtD
Lovastatin—Nausea—Dexamethasone—psoriasis	3.11e-05	0.000373	CcSEcCtD
Lovastatin—Nausea—Betamethasone—psoriasis	3.11e-05	0.000373	CcSEcCtD
Lovastatin—UGT1A1—Metabolism—NDUFA5—psoriasis	3.07e-05	0.000906	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.06e-05	0.000905	CbGpPWpGaD
Lovastatin—SLCO1A2—Transmembrane transport of small molecules—CP—psoriasis	3.05e-05	0.000902	CbGpPWpGaD
Lovastatin—Urticaria—Methotrexate—psoriasis	3.03e-05	0.000363	CcSEcCtD
Lovastatin—Dizziness—Prednisone—psoriasis	3.01e-05	0.000362	CcSEcCtD
Lovastatin—Abdominal pain—Methotrexate—psoriasis	3.01e-05	0.000361	CcSEcCtD
Lovastatin—Body temperature increased—Methotrexate—psoriasis	3.01e-05	0.000361	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	2.98e-05	0.000879	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NOTCH—TP53—psoriasis	2.97e-05	0.000876	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TAGAP—psoriasis	2.97e-05	0.000876	CbGpPWpGaD
Lovastatin—SLCO1A2—Transmembrane transport of small molecules—CARM1—psoriasis	2.91e-05	0.00086	CbGpPWpGaD
Lovastatin—Vomiting—Prednisone—psoriasis	2.9e-05	0.000348	CcSEcCtD
Lovastatin—Rash—Prednisone—psoriasis	2.87e-05	0.000345	CcSEcCtD
Lovastatin—Dermatitis—Prednisone—psoriasis	2.87e-05	0.000345	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—TP53—psoriasis	2.86e-05	0.000845	CbGpPWpGaD
Lovastatin—Headache—Prednisone—psoriasis	2.85e-05	0.000343	CcSEcCtD
Lovastatin—ITGAL—Hemostasis—TP53—psoriasis	2.83e-05	0.000835	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—NDUFA5—psoriasis	2.81e-05	0.00083	CbGpPWpGaD
Lovastatin—Hypersensitivity—Methotrexate—psoriasis	2.81e-05	0.000337	CcSEcCtD
Lovastatin—SLCO1A2—Metabolism—CYP2S1—psoriasis	2.79e-05	0.000825	CbGpPWpGaD
Lovastatin—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	2.78e-05	0.000821	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—TYK2—psoriasis	2.77e-05	0.000819	CbGpPWpGaD
Lovastatin—HDAC2—Circadian rythm related genes—JUN—psoriasis	2.75e-05	0.000814	CbGpPWpGaD
Lovastatin—Asthenia—Methotrexate—psoriasis	2.73e-05	0.000328	CcSEcCtD
Lovastatin—Nausea—Prednisone—psoriasis	2.71e-05	0.000325	CcSEcCtD
Lovastatin—Pruritus—Methotrexate—psoriasis	2.69e-05	0.000323	CcSEcCtD
Lovastatin—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	2.65e-05	0.000783	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.62e-05	0.000774	CbGpPWpGaD
Lovastatin—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	2.61e-05	0.000771	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—CYP2S1—psoriasis	2.61e-05	0.00077	CbGpPWpGaD
Lovastatin—Diarrhoea—Methotrexate—psoriasis	2.61e-05	0.000313	CcSEcCtD
Lovastatin—ITGAL—Immune System—IFNG—psoriasis	2.6e-05	0.000767	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—NDUFA5—psoriasis	2.58e-05	0.000762	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—TYK2—psoriasis	2.57e-05	0.000758	CbGpPWpGaD
Lovastatin—Dizziness—Methotrexate—psoriasis	2.52e-05	0.000302	CcSEcCtD
Lovastatin—ITGAL—Immune System—CD4—psoriasis	2.51e-05	0.000741	CbGpPWpGaD
Lovastatin—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	2.49e-05	0.000736	CbGpPWpGaD
Lovastatin—HDAC2—Factors involved in megakaryocyte development and platelet production—TP53—psoriasis	2.49e-05	0.000734	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—TP53—psoriasis	2.43e-05	0.000717	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.43e-05	0.000717	CbGpPWpGaD
Lovastatin—Vomiting—Methotrexate—psoriasis	2.42e-05	0.000291	CcSEcCtD
Lovastatin—Rash—Methotrexate—psoriasis	2.4e-05	0.000288	CcSEcCtD
Lovastatin—Dermatitis—Methotrexate—psoriasis	2.4e-05	0.000288	CcSEcCtD
Lovastatin—SLCO1B1—Metabolism—CYP2S1—psoriasis	2.39e-05	0.000706	CbGpPWpGaD
Lovastatin—Headache—Methotrexate—psoriasis	2.39e-05	0.000286	CcSEcCtD
Lovastatin—HDAC2—Gene Expression—CARM1—psoriasis	2.32e-05	0.000686	CbGpPWpGaD
Lovastatin—Nausea—Methotrexate—psoriasis	2.26e-05	0.000272	CcSEcCtD
Lovastatin—HMGCR—Metabolism—CARM1—psoriasis	2.26e-05	0.000668	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—JUN—psoriasis	2.25e-05	0.000663	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—CYP2S1—psoriasis	2.19e-05	0.000648	CbGpPWpGaD
Lovastatin—ABCB1—Allograft Rejection—IFNG—psoriasis	2.17e-05	0.000642	CbGpPWpGaD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.17e-05	0.000641	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—NFKB1—psoriasis	2.16e-05	0.000638	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.11e-05	0.000624	CbGpPWpGaD
Lovastatin—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.02e-05	0.000597	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—NFKB1—psoriasis	2e-05	0.000591	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—NOS2—psoriasis	1.99e-05	0.000586	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—STAT3—psoriasis	1.94e-05	0.000574	CbGpPWpGaD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.9e-05	0.00056	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—NDUFA5—psoriasis	1.86e-05	0.000551	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—CARM1—psoriasis	1.84e-05	0.000544	CbGpPWpGaD
Lovastatin—HDAC2—Circadian rythm related genes—TP53—psoriasis	1.82e-05	0.000537	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—STAT3—psoriasis	1.8e-05	0.000531	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CCL20—psoriasis	1.78e-05	0.000525	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.66e-05	0.000492	CbGpPWpGaD
Lovastatin—HDAC2—Circadian rythm related genes—IL6—psoriasis	1.66e-05	0.000492	CbGpPWpGaD
Lovastatin—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.64e-05	0.000485	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—NDUFA5—psoriasis	1.61e-05	0.000477	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—CYP2S1—psoriasis	1.59e-05	0.000468	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—CARM1—psoriasis	1.57e-05	0.000463	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.51e-05	0.000445	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.46e-05	0.000432	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—NDUFA5—psoriasis	1.44e-05	0.000426	CbGpPWpGaD
Lovastatin—ABCB1—Allograft Rejection—TNF—psoriasis	1.41e-05	0.000416	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—NDUFA5—psoriasis	1.41e-05	0.000415	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.4e-05	0.000413	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—CAT—psoriasis	1.39e-05	0.000411	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—VDR—psoriasis	1.39e-05	0.00041	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—CYP2S1—psoriasis	1.37e-05	0.000406	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—CARM1—psoriasis	1.36e-05	0.000403	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—IL6—psoriasis	1.36e-05	0.000401	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.34e-05	0.000397	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—NDUFA5—psoriasis	1.33e-05	0.000392	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—NDUFA5—psoriasis	1.31e-05	0.000388	CbGpPWpGaD
Lovastatin—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.31e-05	0.000386	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.28e-05	0.000377	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—CARM1—psoriasis	1.27e-05	0.000376	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—IL6—psoriasis	1.26e-05	0.000371	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.25e-05	0.00037	CbGpPWpGaD
Lovastatin—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.25e-05	0.000368	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—CYP2S1—psoriasis	1.23e-05	0.000362	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.23e-05	0.000362	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—CYP2S1—psoriasis	1.2e-05	0.000353	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—CARM1—psoriasis	1.17e-05	0.000345	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—VEGFA—psoriasis	1.15e-05	0.00034	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—CAT—psoriasis	1.13e-05	0.000335	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—CYP2S1—psoriasis	1.13e-05	0.000333	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—CYP2S1—psoriasis	1.12e-05	0.00033	CbGpPWpGaD
Lovastatin—HDAC2—Disease—HLA-A—psoriasis	1.1e-05	0.000326	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.09e-05	0.000322	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—APOE—psoriasis	1.08e-05	0.000319	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—CARM1—psoriasis	1.07e-05	0.000316	CbGpPWpGaD
Lovastatin—HDAC2—Disease—APOE—psoriasis	1.03e-05	0.000305	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—SOCS1—psoriasis	9.79e-06	0.000289	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—PPARG—psoriasis	9.67e-06	0.000286	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—CAT—psoriasis	9.64e-06	0.000285	CbGpPWpGaD
Lovastatin—HDAC2—Disease—NOS2—psoriasis	9.61e-06	0.000284	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PPARG—psoriasis	9.41e-06	0.000278	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	9.27e-06	0.000274	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.93e-06	0.000264	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—APOE—psoriasis	8.81e-06	0.00026	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—TP53—psoriasis	8.69e-06	0.000257	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—NDUFA5—psoriasis	8.67e-06	0.000256	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—CAT—psoriasis	8.39e-06	0.000248	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	8.1e-06	0.000239	CbGpPWpGaD
Lovastatin—HDAC2—Disease—TYK2—psoriasis	7.87e-06	0.000232	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—CAT—psoriasis	7.83e-06	0.000231	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—CARM1—psoriasis	7.74e-06	0.000229	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PPARG—psoriasis	7.67e-06	0.000227	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—APOE—psoriasis	7.49e-06	0.000221	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—CYP2S1—psoriasis	7.37e-06	0.000218	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—LEP—psoriasis	7.22e-06	0.000213	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—APOE—psoriasis	7.22e-06	0.000213	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.19e-06	0.000213	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—CAT—psoriasis	7.18e-06	0.000212	CbGpPWpGaD
Lovastatin—HDAC2—Disease—CD4—psoriasis	7.12e-06	0.00021	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.94e-06	0.000205	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—NFKBIA—psoriasis	6.73e-06	0.000199	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—CARM1—psoriasis	6.7e-06	0.000198	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—CAT—psoriasis	6.59e-06	0.000195	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PPARG—psoriasis	6.52e-06	0.000193	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—APOE—psoriasis	6.52e-06	0.000193	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.42e-06	0.00019	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.27e-06	0.000185	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	6.12e-06	0.000181	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—APOE—psoriasis	6.09e-06	0.00018	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—CARM1—psoriasis	5.98e-06	0.000177	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.86e-06	0.000173	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—CARM1—psoriasis	5.84e-06	0.000173	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PPARG—psoriasis	5.68e-06	0.000168	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.59e-06	0.000165	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—APOE—psoriasis	5.58e-06	0.000165	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TYK2—psoriasis	5.51e-06	0.000163	CbGpPWpGaD
Lovastatin—HDAC2—Disease—STAT3—psoriasis	5.51e-06	0.000163	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—CARM1—psoriasis	5.5e-06	0.000163	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—CARM1—psoriasis	5.46e-06	0.000161	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PPARG—psoriasis	5.3e-06	0.000157	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—APOE—psoriasis	5.12e-06	0.000151	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.1e-06	0.000151	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PPARG—psoriasis	4.86e-06	0.000143	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CXCL8—psoriasis	4.8e-06	0.000142	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—CAT—psoriasis	4.76e-06	0.000141	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—JUN—psoriasis	4.46e-06	0.000132	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PPARG—psoriasis	4.46e-06	0.000132	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—NFKB1—psoriasis	4.29e-06	0.000127	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—CAT—psoriasis	4.12e-06	0.000122	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—VEGFA—psoriasis	3.9e-06	0.000115	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—STAT3—psoriasis	3.86e-06	0.000114	CbGpPWpGaD
Lovastatin—HDAC2—Disease—IL6—psoriasis	3.85e-06	0.000114	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—APOE—psoriasis	3.7e-06	0.000109	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—CAT—psoriasis	3.68e-06	0.000109	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—CARM1—psoriasis	3.6e-06	0.000106	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—CAT—psoriasis	3.59e-06	0.000106	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—CAT—psoriasis	3.39e-06	0.0001	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—CAT—psoriasis	3.36e-06	9.91e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PPARG—psoriasis	3.22e-06	9.52e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—APOE—psoriasis	3.2e-06	9.46e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TP53—psoriasis	2.95e-06	8.7e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—APOE—psoriasis	2.86e-06	8.45e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—APOE—psoriasis	2.79e-06	8.25e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PPARG—psoriasis	2.79e-06	8.24e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—IL6—psoriasis	2.7e-06	7.96e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—APOE—psoriasis	2.63e-06	7.77e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—APOE—psoriasis	2.61e-06	7.7e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PPARG—psoriasis	2.49e-06	7.36e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PPARG—psoriasis	2.43e-06	7.18e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PPARG—psoriasis	2.29e-06	6.77e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PPARG—psoriasis	2.27e-06	6.71e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—CAT—psoriasis	2.21e-06	6.54e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—APOE—psoriasis	1.72e-06	5.08e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PPARG—psoriasis	1.5e-06	4.42e-05	CbGpPWpGaD
